The ASXL1 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to eliminate functional expression of the ASXL1 gene in the human embryonic kidney HEK293T cell line. This product delivers a heterogeneous pool of cells harboring targeted disruptions at the ASXL1 locus, providing a versatile loss-of-function model that avoids the clonal selection bottlenecks inherent in monoclonal knockouts. The polyclonal format preserves the genetic diversity of the edited population, enabling robust experimental designs that average out clonal artifacts. By employing CRISPR/Cas9-mediated gene disruption, this system allows researchers to interrogate ASXL1-dependent mechanisms within a well-characterized epithelial background, independent of hematopoietic-specific contexts.
The HEK293T host cell line is a widely utilized derivative of the original HEK293 cells, stably expressing the SV40 large T antigen to facilitate episomal replication of plasmids bearing the SV40 origin of replication. Originally derived from human embryonic kidney, these adherent epithelial cells exhibit high transfection efficiency and robust protein expression capacity, making them a preferred platform for biochemical, proteomic, and viral production studies. Their rapid doubling time and ease of culture further enhance their utility in high-throughput and cell-based assays. The introduction of an ASXL1 knockout within this framework creates a powerful tool for probing epigenetic regulation without the confounding variables of hematopoietic lineage-specific factors.
ASXL1 encodes a chromatin-binding protein that serves as a scaffold for the BAP1 deubiquitinase complex, which removes monoubiquitin from histone H2A at lysine 119 (H2AK119ub), thereby opposing Polycomb repressive complex (PRC)-mediated gene silencing. ASXL1 directly interacts with BAP1, as well as core PRC components including EZH2, SUZ12, and RING1B, and integrates signals from developmental cues such as NOTCH and retinoic acid pathways. Through its association with transcriptional corepressors like NCoR and its regulation by NOTCH1, ASXL1 modulates expression of critical downstream targets??most notably the HOX gene clusters??thereby controlling myeloid differentiation and cell cycle progression. Disruption of this balance is mechanistically linked to hematopoietic stem cell maintenance failure and myeloid oncogenesis.
While ASXL1 mutations are primarily associated with myelodysplastic syndromes, acute myeloid leukemia, chronic myelomonocytic leukemia, and the developmental disorder Bohring-Opitz syndrome, the HEK293T knockout model permits dissection of its epigenetic functions in a non-hematopoietic context. This allows researchers to study the fundamental biochemistry of ASXL1-dependent H2AK119ub deubiquitination, Polycomb complex dynamics, and HOX gene regulation independent of specialized hematopoietic niche factors. The epithelial origin of HEK293T cells provides a clean background for examining how ASXL1 loss alters chromatin landscapes, protein?Cprotein interactions, and transcriptional networks in a highly manipulable system, facilitating the identification of conserved molecular mechanisms relevant to both normal development and disease.
This polyclonal knockout cell population is ideally suited for a broad array of experimental applications. Researchers can employ western blotting and immunofluorescence to monitor global changes in H2AK119ub and other histone modifications, while ChIP-qPCR permits locus-specific analysis of ASXL1 and Polycomb component occupancy at HOX gene promoters. Co-immunoprecipitation and mass spectrometry enable mapping of ASXL1 interaction networks with BAP1, EZH2, SUZ12, and NCoR. Transcriptional profiling via RNA-seq and reporter gene assays can elucidate ASXL1-driven regulatory programs. Furthermore, proliferation assays and drug screening campaigns targeting myeloid malignancy vulnerabilities can be conducted in this convenient cellular platform. For further information or technical support, please contact Ascent Research.
